AlphaSeq will be used to interrogate newly discovered interactions between E3 ubiquitin ligases and therapeutic targets to assess glueability and provide structural insights for molecular glue discovery.
SEATTLE, Sept. 26, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio (A-Alpha), a synthetic biology and machine learning company that measures and engineers protein-protein interactions, today announced the expansion of their collaboration with Amgen's Induced Proximity Platform to characterize interactions between ligases and molecular glue targets for protein degradation.
As part of a research collaboration initiated in 2022 with Amgen, a leading biotechnology company, A-Alpha discovered several weakly interacting ligase-target pairs between a list of Amgen's targets and A-Alpha's proprietary library of E3 ubiquitin ligases. Following review of the results from the initial collaboration and additional work carried out by Amgen, A-Alpha and Amgen have agreed to an expanded collaboration. Under the expanded collaboration agreement, A-Alpha will further interrogate selected pairs to evaluate glueability and provide structural insights expected to enable rational design of molecular glue degraders. A-Alpha Bio will receive an upfront payment and will be eligible for milestones and a royalty on product sales resulting from licensed ligase-target pairs.
"Our work with Amgen over the past six months has been exciting and fruitful. We have enjoyed collaborating with an incredible industry-leading team on this major area of interest," said David Younger, CEO and Co-Founder of A-Alpha Bio. "We look forward to expanding our collaboration and moving into the validation of glueability and the generation of data to inform rational molecular glue discovery. Combining our technology and expertise with Amgen's has the potential to generate high-impact therapeutics and advance our mission to improve human health."
To learn more about A-Alpha Bio and the AlphaSeq platform, please visit: https://www.aalphabio.com/.
About A-Alpha Bio
A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
The company's AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company's AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.
A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/
SOURCE A-Alpha Bio